V. Semiglazov

Abstract S3-2: Neoadjuvant Pertuzumab (P) and Trastuzumab (H): Antitumor and Safety Analysis of a Randomized Phase II Study ('NeoSphere')

Y. Im, L. Gianni, T. Pieńkowski, 2010 .

The Senologic International Society Survey on Ductal Carcinoma In Situ: Present and Future.

V. Ostapenko, X. Hao, T. Pieńkowski, 2022, European journal of breast health.

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIP Michelangelo randomized study.

P. Valagussa, S. Russo, R. Greil, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial

G. Viale, L. De Cecco, M. Dugo, 2021, Molecular oncology.

Comparing Neoadjuvant Nab-paclitaxel vs Paclitaxel Both Followed by Anthracycline Regimens in Women With ERBB2/HER2-Negative Breast Cancer—The Evaluating Treatment With Neoadjuvant Abraxane (ETNA) Trial: A Randomized Phase 3 Clinical Trial

L. Gianni, P. Valagussa, L. Calvo, 2018, JAMA oncology.

Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial

R. Greil, B. Győrffy, Esther Danenberg, 2022, Cancer Research.

Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer

J. Herranz, J. Albanell, L. Gianni, 2022, Frontiers in Oncology.

Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies.

L. Carey, A. Lluch, L. Gianni, 2018, Annals of Oncology.

Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial

R. Greil, D. Ross, B. Győrffy, 2022, Cancer Research.

LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial

B. Győrffy, M. Dugo, M. Callari, 2021, Annals of Oncology.

LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial

R. Greil, G. Viale, L. Gianni, 2020 .

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial.

L. Pusztai, A. Lluch, V. Semiglazov, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Spatial predictors of immunotherapy response in triple-negative breast cancer

P. Valagussa, H. R. Ali, M. Colleoni, 2023, Nature.

Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.

J. Baselga, W. Eiermann, A. Lluch, 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.